Robert S Wallis

Case Western Reserve University School of Medicine, Cleveland, Ohio, United States

Are you Robert S Wallis?

Claim your profile

Publications (114)692.4 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Sutezolid (PNU-100480) is a linezolid analog with superior bactericidal activity against Mycobacterium tuberculosis in the hollow fiber, whole blood and mouse models. Like linezolid, it is unaffected by mutations conferring resistance to standard TB drugs. This study of sutezolid is its first in tuberculosis patients. Sputum smear positive tuberculosis patients were randomly assigned to sutezolid 600 mg BID (N = 25) or 1200 mg QD (N = 25), or standard 4-drug therapy (N = 9) for the first 14 days of treatment. Effects on mycobacterial burden in sputum (early bactericidal activity or EBA) were monitored as colony counts on agar and time to positivity in automated liquid culture. Bactericidal activity was also measured in ex vivo whole blood cultures (whole blood bactericidal activity or WBA) inoculated with M. tuberculosis H37Rv. All patients completed assigned treatments and began subsequent standard TB treatment according to protocol. The 90% confidence intervals (CI) for bactericidal activity in sputum over the 14 day interval excluded zero for all treatments and both monitoring methods, as did those for cumulative WBA. There were no treatment-related serious adverse events, premature discontinuations, or dose reductions due to laboratory abnormalities. There was no effect on the QT interval. Seven sutezolid-treated patients (14%) had transient, asymptomatic ALT elevations to 173±34 U/L on day 14 that subsequently normalized promptly; none met Hy's criteria for serious liver injury. The mycobactericidal activity of sutezolid 600 mg BID or 1200 mg QD was readily detected in sputum and blood. Both schedules were generally safe and well tolerated. Further studies of sutezolid in tuberculosis treatment are warranted. NCT01225640.
    PLoS ONE 04/2014; 9(4):e94462. · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tuberculosis (TB) is an airborne infectious disease that kills almost 2 million individuals every year. Multidrug-resistant (MDR) TB is caused by strains of Mycobacterium tuberculosis (M. tb) resistant to isoniazid and rifampin, the backbone of first-line antitubercular treatment. MDR-TB affects an estimated 500,000 new patients annually. Genetic analysis of drug-resistant MDR-TB showed that airborne transmission of undetected and untreated strains played a major role in disease outbreaks. The need for new TB vaccines and faster diagnostics, as well as the development of new drugs, has recently been highlighted. The major problem in terms of current TB research and clinical demands is the increasing number of cases of extensively drug-resistant and ‘treatment-refractory’ TB. An emerging scenario of adjunct host-directed therapies is intended to target pulmonary TB where inflammatory processes can be deleterious and lead to immune exhaustion. ‘Target-organ saving’ strategies may be warranted to prevent damage to infected tissues and achieve focused, clinically relevant and long-lasting anti-M. tb-directed cellular immune responses. Candidates for such interventions may be biological agents or already approved drugs that can be ‘re-purposed’ to interfere with biologically relevant cellular checkpoints. Here we review current concepts of inflammation in TB disease and discuss candidate pathways for host-directed therapies in order to achieve better clinical outcomes.This article is protected by copyright. All rights reserved.
    Journal of Internal Medicine 04/2014; · 5.79 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background:Sutezolid (PNU-100480 or U-480) is an oxazolidinone antimicrobial being developed for treatment of tuberculosis. An active sulfoxide metabolite (PNU-101603 or U-603), which reaches concentrations in plasma several times those of the parent, has been reported to drive killing of extracellular M. tuberculosis by sutezolid in hollow fiber culture. However, the relative contributions of parent and metabolite against intracellular M. tuberculosis in vivo are not fully understood.Methods:The relationships between plasma concentrations of U-480 and U-603 and intracellular whole blood bactericidal activity (WBA) in ex vivo cultures were examined using a direct competitive population PK-PD 4 parameter sigmoid model. The dataset included 690 PK and 345 WBA determinations from 50 tuberculosis patients enrolled in a phase 2 sutezolid trial. The model parameters were solved iteratively.Results:The median U-603/U-480 concentration ratio was 7.1 (range, 1 to 28). The apparent U-603 IC50 for intracellular M. tuberculosis was 17-fold greater than U-480 (90% CI, 9.9 to 53). Model parameters were used to simulate in vivo activity after oral dosing with sutezolid 600 mg BID and 1200 mg QD. Divided dosing resulted a greater cumulative activity (-.269 log10 per day, 90% CI: -.237 to -.293) compared to single daily dosing (-.186, 90% CI: -.160 to -.208). U-480 accounted for 84% and 78% of activity for BID and QD dosing, respectively, despite the higher concentrations of U-603.Conclusions:Killing of intracellular M. tuberculosis by orally administered sutezolid is mainly due to activity of the parent compound. Taken together with other studies in the hollow fiber model, these findings suggest sutezolid and its metabolite act on different mycobacterial subpopulations.
    Antimicrobial Agents and Chemotherapy 03/2014; · 4.57 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite the widespread use of the BCG vaccine there are more than 9 million new cases of tuberculosis (TB) every year and there is an urgent need for better TB vaccines. TB vaccine candidates are selected for evaluation based in part on the detection of an antigen-specific IFN-γ response. The measurement of mycobacterial growth in blood specimens obtained from subjects immunized with investigational TB vaccines may be a better in vitro correlate of in vivo vaccine efficacy. We performed a clinical study with 30 UK adults who were followed for 6 months to evaluate the ability of both a whole blood and a novel PBMC based mycobacterial growth inhibition assay to measure a response to primary vaccination and revaccination with BCG. Using cryopreserved PBMC we observed a significant improvement in mycobacterial growth inhibition following primary vaccination, but no improvement in growth inhibition following revaccination with BCG (p<0.05). Mycobacterial growth inhibition following primary BCG vaccination was not correlated with PPD antigen specific IFN- γ ELISPOT responses. We demonstrate that a mycobacterial growth inhibition assay can detect improved capacity to control growth following primary immunization but not revaccination with BCG. This is the first study to demonstrate that an in vitro growth inhibition assay can identify a difference in a vaccine response comparing both primary and secondary BCG vaccination, suggesting that in vitro growth inhibition assays may serve as better surrogates of clinical efficacy than those assays currently used for the assessment of candidate TB vaccines.
    Clinical and vaccine Immunology: CVI 08/2013; · 2.37 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: New drugs and regimens with the potential to transform tuberculosis treatment are presently in early stage clinical trials. The goal of the present study was to infer the required duration of these treatments. A meta-regression model was developed to predict relapse risk using treatment duration and month 2 sputum culture positive rate as predictors, based on published historical data from 24 studies describing 58 regimens in 7793 patients. Regimens in which rifampin was administered for the first 2 months but not subsequently were excluded. The model treated study as a random effect. The model predicted that new regimens of 4 or 5 months duration with rates of culture positivity after 2 months of 1% or 3%, would yield relapse rates of 4.0% or 4.1%, respectively. In both cases, the upper limit of the 2-sided 80% prediction interval for relapse for a hypothetical trial with 680 subjects per arm was <10%. Analysis using this model of published month 2 data for moxifloxacin-containing regimens indicated they would result in relapse rates similar to standard therapy only if administered for ≥5 months. This model is proposed to inform the required duration of treatment of new TB regimens, potentially hastening their accelerated approval by several years.
    PLoS ONE 08/2013; 8(8):e71116. · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Biomarkers are indispensable to the development of new tuberculosis therapeutics and vaccines. The most robust biomarkers measure factors that are essential to the underlying pathological process of the disease being treated, and thus can capture the full effects of many types of interventions on clinical outcomes in multiple prospective, randomised clinical trials. Many Mycobacterium tuberculosis and human biomarkers have been studied over the past decade. Present research focuses on three areas: biomarkers predicting treatment efficacy and cure of active tuberculosis, the reactivation of latent tuberculosis infection, and the induction of protective immune responses by vaccination. Many older, non-specific markers of inflammation, when considered in isolation, do not have sufficient predictive values for clinical use in tuberculosis. Although no new accurate, tuberculosis-specific biomarkers have yet been discovered, substantial progress has been made in some areas. However, the qualification of biomarkers as a surrogate for a clinical endpoint in tuberculosis is very challenging, and, for biomarkers that are non-culture-based, impossible to pursue without the availability of well characterised biobanks containing biospecimens from patients who have had adequate follow-up to establish long-term treatment outcome. We review progress in tuberculosis biomarker development and efforts being made to harness resources to meet future challenges.
    The Lancet Infectious Diseases 03/2013; · 19.45 Impact Factor
  • Robert S Wallis, Carol Nacy
    The Lancet 01/2013; 381(9861):111-2. · 39.21 Impact Factor
  • Source
    Robert S Wallis
    [Show abstract] [Hide abstract]
    ABSTRACT: Six new antituberculosis compounds in 4 classes are presently in clinical trials. Although these show substantial promise for drug-resistant (DR) tuberculosis, the presently planned studies of these compounds will not inform their optimal use, as each will be tested singly vs placebo with existing drugs, rather than in new regimens. Each successive regulatory approval will increase the size, cost, and complexity of trials for those that follow, causing delays during which suboptimal use will occur and resistance will emerge. This paper proposes the development of a novel regimen with the potential for use in both drug-sensitive (DS) and DR tuberculosis. Adaptive licensing for DR tuberculosis based on 2-month sputum culture would shorten time to initial approval by several years. A global outcomes registry would confirm safety and effectiveness in both DS and DR tuberculosis, making possible the second transformation of tuberculosis treatment. We should do our utmost to see it succeed.
    Clinical Infectious Diseases 10/2012; · 9.42 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Novel oral regimens composed of new drugs with potent activity against Mycobacterium tuberculosis and no cross-resistance with existing agents are needed to shorten and simplify treatment for both drug-susceptible and drug-resistant tuberculosis. As part of a continuing effort to evaluate novel drug combinations for treatment-shortening potential in a murine model, we performed two long-term, relapse-based experiments. In the first experiment, several 3- and 4-drug combinations containing new agents currently in phase 2/3 trials (TMC207 [bedaquiline], PA-824 and PNU-100480 [sutezolid], and/or clofazimine) proved superior to the first-line regimen of rifampin, pyrazinamide, and isoniazid. TMC207 plus PNU-100480 was the most effective drug pair. In the second experiment, in which 3- and 4-drug combinations composed of TMC207 and pyrazinamide plus rifapentine, clofazimine, PNU-100480, or both rifapentine and clofazimine were evaluated, the rank order of drugs improving the sterilizing activity of TMC207 and pyrazinamide was as follows: rifapentine plus clofazimine ≥ clofazimine ≥ rifapentine > PNU-100480. The results revealed potential new building blocks for universally active short-course regimens for drug-resistant tuberculosis. The inclusion of pyrazinamide against susceptible isolates may shorten the duration of treatment further.
    Antimicrobial Agents and Chemotherapy 04/2012; 56(6):3114-20. · 4.57 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There presently is no rapid method to assess the bactericidal activity of new regimens for tuberculosis. This study examined PNU-100480, TMC207, PA-824, SQ109, and pyrazinamide, singly and in various combinations, against intracellular M. tuberculosis, using whole blood culture (WBA). The addition of 1,25-dihydroxy vitamin D facilitated detection of the activity of TMC207 in the 3-day cultures. Pyrazinamide failed to show significant activity against a PZA-resistant strain (M. bovis BCG), and was not further considered. Low, mid, and high therapeutic concentrations of each remaining drug were tested individually and in a paired checkerboard fashion. Observed bactericidal activity was compared to that predicted by the sum of the effects of individual drugs. Combinations of PNU-100480, TMC207, and SQ109 were fully additive, whereas those including PA-824 were less than additive or antagonistic. The cumulative activities of 2, 3, and 4 drug combinations were predicted based on the observed concentration-activity relationship, published pharmacokinetic data, and, for PNU-100480, published WBA data after oral dosing. The most active regimens, including PNU-100480, TMC207, and SQ109, were predicted to have cumulative activity comparable to standard TB therapy. Further testing of regimens including these compounds is warranted. Measurement of whole blood bactericidal activity can accelerate the development of novel TB regimens.
    PLoS ONE 01/2012; 7(1):e30479. · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate in vitro interaction between two compounds, SQ109 and PNU-100480, currently in development for the treatment of Mycobacterium tuberculosis (MTB). The two-drug interactions between SQ109 and PNU-100480 and its major metabolite PNU-101603 were assessed by chequerboard titration, and the rate of killing and intracellular activity were determined in both J774A.1 mouse macrophages and whole blood culture. In chequerboard titration, interactions between SQ109 and either oxazolidinone were additive. In time-kill studies, SQ109 killed MTB faster than PNU compounds, and its rate of killing was further enhanced by both oxazolidinones. The order of efficacy of single compounds against intracellular MTB was SQ109 > PNU-100480 > PNU-101603. At sub-MIC, combinations of SQ109 + PNU compounds showed improved intracellular activity over individual drugs; at ≥MIC, the order of efficacy was SQ109 > SQ109 + PNU-100480 > SQ109 + PNU-101603. In whole blood culture, the combined bactericidal activities of SQ109 and PNU-100480 and its major metabolite against intracellular M. tuberculosis did not differ significantly from the sum of the compounds tested individually. SQ109 and PNU combinations were additive and improved the rate of MTB killing over individual drugs. These data suggest that the drugs may work together cooperatively to eliminate MTB in vivo.
    Journal of Antimicrobial Chemotherapy 01/2012; 67(5):1163-6. · 5.34 Impact Factor
  • Robert S Wallis
    [Show abstract] [Hide abstract]
    ABSTRACT: In the decade since tumor necrosis factor α (TNF-α) antagonists were first approved for clinical use, they have proven invaluable for the treatment of specific types of chronic inflammation. Currently licensed TNF blockers fall into two classes, monoclonal antibody (or antibody fragments) and soluble receptor. Although they are equally effective in rheumatoid arthritis and psoriasis, important differences have emerged with regard to efficacy in granulomatous inflammation and risks of granulomatous infections, particularly tuberculosis. This article focuses on recent studies that inform prevention and management of infections in this susceptible patient population.
    Infectious disease clinics of North America 12/2011; 25(4):895-910. · 2.29 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tuberculosis is a serious global health threat for which new treatments are urgently needed. This study examined the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses of the oxazolidinone PNU-100480 in healthy volunteers, using biomarkers for safety and efficacy. Subjects were randomly assigned to PNU-100480 or placebo (4:1) at schedules of 100, 300, or 600 mg twice daily or 1,200 mg daily for 14 days or a schedule of 600 mg twice daily for 28 days to which pyrazinamide was added on days 27 and 28. A sixth cohort was given linezolid at 300 mg daily for 4 days. Signs, symptoms, and routine safety tests were monitored. Bactericidal activity against Mycobacterium tuberculosis was measured in ex vivo whole-blood culture. Plasma drug and metabolite concentrations were compared to the levels required for inhibition of M. tuberculosis growth and 50% inhibition of mitochondrial protein synthesis. All doses were safe and well tolerated. There were no hematologic or other safety signals during 28 days of dosing at 600 mg twice daily. Plasma concentrations of PNU-100480 and metabolites at this dose remained below those required for 50% inhibition of mitochondrial protein synthesis. Cumulative whole-blood bactericidal activity of PNU-100480 at this dose (-0.316 ± 0.04 log) was superior to the activities of all other doses tested (P < 0.001) and was significantly augmented by pyrazinamide (-0.420 ± 0.06 log) (P = 0.002). In conclusion, PNU-100480 was safe and well tolerated at all tested doses. Further studies in patients with tuberculosis are warranted. Biomarkers can accelerate early development of new tuberculosis treatments.
    Antimicrobial Agents and Chemotherapy 11/2010; 55(2):567-74. · 4.57 Impact Factor
  • Source
    Robert S Wallis, Neil W Schluger
    [Show abstract] [Hide abstract]
    ABSTRACT: The understanding of the infection risks posed by tumor necrosis factor (TNF) antagonists has continued to evolve in the 10 years since these drugs first were introduced. Recent prospective studies have confirmed the risk of tuberculosis (TB) reactivation posed by TNF antibodies to be several fold greater than soluble TNF receptor. Certolizumab pegol, a monovalent anti-TNF Fab' fragment, appears to share this risk, despite its lack of Fc and its inability to cross-link transmembrane TNF or activate complement. Two-step (boosted) tuberculin skin test screening and initiation of treatment for latent TB infection can greatly reduce the TB risk of anti-TNF treatment in western countries. Current recommendations for withdrawal of anti-TNF therapy when TB is diagnosed place patients at risk for paradoxical worsening due to recovery of TNF-dependent inflammation. Further research is needed to determine how best to prevent and manage their infectious complications and to determine their potential adjunctive therapeutic role in chronic infectious diseases.
    Infectious disease clinics of North America 09/2010; 24(3):681-92. · 2.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The oxazolidinone PNU-100480 is superior to linezolid against experimental murine tuberculosis. Two metabolites contribute to but do not fully account for its superiority. This study examined the safety, tolerability, pharmacokinetics, and mycobactericidal activity of single ascending doses of PNU-100480. Nineteen healthy volunteers received 2 escalating single oral doses (35-1500 mg) of PNU-100480 or placebo. Eight subjects received 4 daily doses of 300 mg of linezolid. Drug concentrations and bactericidal activity against Mycobacterium tuberculosis in whole-blood bactericidal culture were measured. All doses were safe and well tolerated. PNU-100480 doses to 1000 mg were well absorbed and showed approximately proportional increases in exposures of parent and metabolites. The geometric mean maximal concentrations of PNU-100480, PNU-101603, and PNU-101244 (sulfoxide and sulfone metabolites) at 1000 mg were 839, 3558, and 54 ng/mL, respectively. The maximal whole-blood bactericidal activity (-0.37 +/- .06 log/day) occurred at combined PNU levels > or =2 times the minimum inhibitory concentration. The observed geometric mean maximal concentration for linezolid was 6425 ng/mL. Its maximal whole-blood bactericidal activity also occurred at > or =2 times the minimum inhibitory concentration, but it was only -0.16 +/- .05 log/day (P< .001) Neither drug showed enhanced activity at higher concentrations. Single doses of PNU-100480 to 1000 mg were well tolerated and exhibited antimycobacterial activity superior to 300 mg of linezolid at steady state. Additional studies are warranted to define its role in drug-resistant tuberculosis.
    The Journal of Infectious Diseases 09/2010; 202(5):745-51. · 5.85 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Human infection with Mycobacterium tuberculosis can progress to active disease, be contained as latent infection, or be eradicated by the host response. Tuberculosis diagnostics classify a patient into one of these categories. These are not fixed distinct states, but rather are continua along which patients can move, and are affected by HIV infection, immunosuppressive therapies, antituberculosis treatments, and other poorly understood factors. Tuberculosis biomarkers-host or pathogen-specific-provide prognostic information, either for individual patients or study cohorts, about these outcomes. Tuberculosis case detection remains difficult, partly because of inaccurate diagnostic methods. Investments have yielded some progress in development of new diagnostics, although the existing pipeline is limited for tests for sputum-smear-negative cases, childhood tuberculosis, and accurate prediction of reactivation of latent tuberculosis. Despite new, sensitive, automated molecular platforms for detection of tuberculosis and drug resistance, a simple, inexpensive point-of-care test is still not available. The effect of any new tests will depend on the method and extent of their introduction, the strength of the laboratories, and the degree to which access to appropriate therapy follows access to diagnosis. Translation of scientific progress in biomarkers and diagnostics into clinical and public health programmes is possible-with political commitment, increased funding, and engagement of all stakeholders.
    The Lancet 05/2010; 375(9729):1920-37. · 39.21 Impact Factor
  • Source
    The Lancet Infectious Diseases 02/2010; 10(2):68-9. · 19.45 Impact Factor
  • Robert S Wallis, T Mark Doherty, Alimuddin Zumla
    The Lancet Infectious Diseases 02/2010; 10(2):70-1. · 19.45 Impact Factor
  • Source
    T Mark Doherty, Robert S Wallis, Alimuddin Zumla
    [Show abstract] [Hide abstract]
    ABSTRACT: The changing face of tuberculosis, with epidemics fueled by HIV and urbanization in much of the world and a relative increase in the importance of latent tuberculosis as a source of cases in the more economically developed countries, has led to a demand for more robust, clinically applicable diagnostic tools. As a result, research aiming to identify biomarkers of Mycobacterium tuberculosis infection and disease has flourished. This article discusses the most recent findings of that work.
    Clinics in chest medicine 12/2009; 30(4):783-96, x. · 2.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Immunotherapies have the potential to improve the outcome in all patients with tuberculosis (TB) including those with multidrug-resistant (MDR)-TB and extensively drug-resistant (XDR)-TB. Immunotherapy for TB may shorten duration of treatment and reduce pathology in individuals cured by chemotherapy, potentially preventing recurrence. Currently none of the available candidate agents have proof of efficacy for use in MDR-TB or XDR-TB. Further development and evaluation of existing immunotherapeutic agents is required to identify an effective agent that can be used adjunctively with chemotherapy to improve treatment outcomes for drug-susceptible TB, MDR-TB, and XDR-TB. With a range of potential immunotherapeutics, some of which have been produced to good manufacturing practice (GMP) standards and are registered for other indications in humans, the immunotherapy option should no longer be ignored.
    Clinics in chest medicine 12/2009; 30(4):769-82, ix. · 2.51 Impact Factor

Publication Stats

4k Citations
692.40 Total Impact Points


  • 1992–2014
    • Case Western Reserve University School of Medicine
      • Department of Medicine
      Cleveland, Ohio, United States
  • 2010–2013
    • Pfizer Inc.
      New York City, New York, United States
  • 2009
    • Statens Serum Institut
      • Department of Infectious Disease Immunology
      København, Capital Region, Denmark
  • 2008
    • Capital & Coast District Health Board
      Wellington, Wellington, New Zealand
  • 2005–2007
    • PPD
      Wilmington, North Carolina, United States
  • 2001–2006
    • Rutgers New Jersey Medical School
      • Department of Medicine (RWJ Medical School)
      Newark, NJ, United States
  • 1987–2004
    • Case Western Reserve University
      • • School of Medicine
      • • Department of Medicine (University Hospitals Case Medical Center)
      • • Division of Infectious Diseases and HIV Medicine
      Cleveland, Ohio, United States
  • 2002
    • Ewha Womans University
      Sŏul, Seoul, South Korea
  • 2000–2001
    • Aga Khan University Hospital, Karachi
      Kurrachee, Sindh, Pakistan
  • 1997
    • Institute of Tropical Medicine
      Antwerpen, Flanders, Belgium